VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Eric Van Cutsem on Regorafenib for Metastatic Colorectal Cancer

Eric Van Cutsem, MD, PhD
Published: Friday, Jul 03, 2015



Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).

There were minimal toxicities in the study, and all were consistent with what was found in the CORRECT study, which also investigated regorafenib in mCRC, said Van Cutsem. There were no new safety concerns found, although 40-50% of patients did require some dose modification. Common toxicities included hypertension, fatigue, and hand-foot-skin reaction. 

Progression-free survival was also similar to the CORRECT study, which validated regorafenib's efficacy in a larger population, said Van Cutsem.

<<< View more from the 2015 World GI Congress



Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).

There were minimal toxicities in the study, and all were consistent with what was found in the CORRECT study, which also investigated regorafenib in mCRC, said Van Cutsem. There were no new safety concerns found, although 40-50% of patients did require some dose modification. Common toxicities included hypertension, fatigue, and hand-foot-skin reaction. 

Progression-free survival was also similar to the CORRECT study, which validated regorafenib's efficacy in a larger population, said Van Cutsem.

<<< View more from the 2015 World GI Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x